MTOR and breast carcinoma: Because the PI3K/Akt/mTOR pathway is frequently deregulated in breast cancers, mTORC1 inhibitors have been used in the clinic, but the success of rapalogues has been thwarted due to the activation of Akt involving a negative feedback loop [17].